Shares of leading US homebuilders have plummeted since an industry-wide peak in July, according to a Financial Times analysis.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The U.S. Securities and Exchange Commission announced that it charged BlackRock – the largest money manager in the world, with nearly $10 trillion in…
Goldman Sachs is launching a sort of geopolitics-slash-technology research arm to advise clients who get anxious when they turn the news on.
The former chief executive of Alameda and star witness in the trial of her boss and former romantic partner, FTX co-founder Sam Bankman-Fried, described…
The UK’s Financial Conduct Authority said Tuesday that it’s ending a cap on bonuses for bankers that’s been in place since 2014.
On Monday, Chevron said it would acquire energy player Hess for $53 billion. It’s the latest megadeal in a wildly active industry this month.
As recently as 2021, the industry set a record by generating $1.4 trillion via outright sales or IPOs of portfolio companies. (A person could live on…
Goldman Sachs saw its profits slump 33% in its latest quarter, as the bank continues retreating from the consumer banking sector.
With economic uncertainty looming over the finance industry, a handful of the most popular firms have cut back their MBA hiring efforts.
Wall Street legend Carl Icahn bet big and — so far — has lost big on a wager against US shopping malls by way of a risky derivative strategy.
Experts weigh in on how the crypto king, Sam Bankman-Fried, got lost in the casino.
Star witness and Sam Bankman-Fried’s former girlfriend of Sam Bankman-Fried, Caroline Ellison, says he directed the crimes.
Despite conservative disdain for ESG initiatives, one research project found climate change remains a chief concern for asset managers.
JP Morgan, the largest bank in America, with more than $3 trillion in assets, settles all Epstein lawsuits.
Goldman Sachs launched its ETF accelerator platform, intended to help smaller third-party funds enter the $10 trillion market.
Some of pharma’s biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.